{"id":779820,"date":"2025-12-15T13:17:02","date_gmt":"2025-12-15T13:17:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=779820"},"modified":"2025-12-15T13:17:02","modified_gmt":"2025-12-15T13:17:02","slug":"endra-life-sciences-nasdaq-ndra-advances-health-tech-alongside-kytx-radx-glsi-imnm-with-a-nextgeneration-treasury-strategy","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/endra-life-sciences-nasdaq-ndra-advances-health-tech-alongside-kytx-radx-glsi-imnm-with-a-nextgeneration-treasury-strategy_779820.html","title":{"rendered":"ENDRA Life Sciences (NASDAQ: NDRA) Advances Health Tech (Alongside KYTX, RADX, GLSI IMNM) With a Next-Generation Treasury Strategy"},"content":{"rendered":"
\"ENDRA<\/a><\/div>\n

 <\/p>\n

ENDRA Life Sciences (NASDAQ: NDRA)<\/strong> is emerging as a differentiated small-cap opportunity by combining breakthrough medical imaging innovation<\/strong> with a next-generation treasury strategy<\/strong> designed to improve capital efficiency and accelerate growth. The company, developer of the TAEUS® (Thermo-Acoustic Enhanced UltraSound)<\/strong> system for liver disease, is addressing one of healthcare’s largest unmet needs while modernizing how it manages and deploys corporate capital.<\/p>\n

TAEUS® Targets a Massive, Underdiagnosed Market<\/strong><\/p>\n

TAEUS® is designed to provide clinicians with real-time insight into tissue composition, function, and temperature at the point of care—capabilities traditionally limited to CT or MRI, but at a fraction of the cost. Its primary focus is steatotic liver disease (SLD)<\/strong> and metabolic dysfunction–associated steatohepatitis (MASH)<\/strong>, conditions affecting more than 2 billion people globally<\/strong> and roughly one-third of the U.S. population<\/strong>.<\/p>\n

Recent strategic positioning has aligned TAEUS® with the rapidly expanding GLP-1 therapy market<\/strong>, projected to exceed $100 billion<\/strong>. As metabolic disorders rise and GLP-1 treatments gain adoption, demand for non-invasive, cost-effective liver monitoring is expected to grow significantly—creating a compelling use case for TAEUS® as a scalable, point-of-care solution.<\/p>\n

Along with <\/strong>ENDRA Life Sciences Inc (NASDAQ: NDRA<\/strong>), see Innovative Healthcare Stocks to Watch Now: <\/strong>Kyverna Therapeutics, Inc. (Nasdaq: KYTX<\/strong>), Radiopharm Theranostics (Nasdaq: RADX<\/strong>), Greenwich LifeSciences (Nasdaq: GLSA<\/strong>) and Immunome (Nasdaq: IMNM<\/strong>) all active in intraday trading sessions.<\/strong><\/p>\n

First-Mover Advantage Backed by Clinical Momentum<\/strong><\/p>\n

Unlike traditional imaging modalities, TAEUS® delivers quantitative liver fat assessment in real time at the point of care<\/strong>, avoiding the high cost and logistical barriers of MRI or CT. ENDRA’s multisite pilot studies and recently reported feasibility data—demonstrating strong alignment with MRI-PDFF at clinically meaningful thresholds—reinforce the platform’s potential for use in routine care and pharmaceutical trials.<\/p>\n

Next-Generation Treasury Strategy Fuels Non-Dilutive Growth<\/strong><\/p>\n

What sets ENDRA apart from many early-stage medtech peers is its Next-Generation Treasury strategy<\/strong>, managed by Arca Investment Management<\/strong>. This approach transforms idle cash into a structured, yield-generating growth engine<\/strong>, leveraging institutional-grade treasury techniques historically available only to large financial institutions.<\/p>\n

The strategy emphasizes:<\/p>\n